SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Drdgold Ltd – ‘20-F’ for 12/14/07 – EX-99

On:  Friday, 12/14/07, at 11:48am ET   ·   For:  12/14/07   ·   Accession #:  1205613-7-166   ·   File #:  0-28800

Previous ‘20-F’:  ‘20-F/A’ on / for 12/13/07   ·   Next:  ‘20-F’ on / for 12/12/08   ·   Latest:  ‘20-F/A’ on 10/31/23 for 6/30/23   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

12/14/07  Drdgold Ltd                       20-F       12/14/07   38:12M                                    Ince Pty Ltd/FA

Annual Report of a Foreign Private Issuer   —   Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report of a Foreign Private Issuer           HTML   1.92M 
 2: 20-F        Annual Report of a Foreign Private Issuer --         PDF   1.93M 
                          drd_20f                                                
 3: EX-99       Miscellaneous Exhibit                               HTML     21K 
 5: EX-99       Miscellaneous Exhibit                               HTML     21K 
 7: EX-99       Miscellaneous Exhibit                               HTML     14K 
 9: EX-99       Miscellaneous Exhibit                               HTML     14K 
12: EX-99       Miscellaneous Exhibit                               HTML     71K 
13: EX-99       Miscellaneous Exhibit                               HTML    133K 
15: EX-99       Miscellaneous Exhibit                               HTML    235K 
17: EX-99       Miscellaneous Exhibit                               HTML    251K 
19: EX-99       Miscellaneous Exhibit                               HTML    211K 
21: EX-99       Miscellaneous Exhibit                               HTML     46K 
23: EX-99       Miscellaneous Exhibit                               HTML    113K 
25: EX-99       Miscellaneous Exhibit                               HTML    220K 
27: EX-99       Miscellaneous Exhibit                               HTML     63K 
29: EX-99       Miscellaneous Exhibit                               HTML    135K 
31: EX-99       Miscellaneous Exhibit                               HTML    346K 
33: EX-99       Miscellaneous Exhibit                               HTML     50K 
35: EX-99       Miscellaneous Exhibit                               HTML    106K 
37: EX-99       Miscellaneous Exhibit                               HTML     14K 
 4: EX-99       Miscellaneous Exhibit -- ex12_1                      PDF     92K 
 6: EX-99       Miscellaneous Exhibit -- ex12_2                      PDF     91K 
 8: EX-99       Miscellaneous Exhibit -- ex13_1                      PDF     65K 
10: EX-99       Miscellaneous Exhibit -- ex13_2                      PDF     64K 
11: EX-99       Miscellaneous Exhibit -- ex4_111                     PDF    140K 
14: EX-99       Miscellaneous Exhibit -- ex4_112                     PDF    203K 
16: EX-99       Miscellaneous Exhibit -- ex4_113                     PDF    312K 
18: EX-99       Miscellaneous Exhibit -- ex4_114                     PDF    385K 
20: EX-99       Miscellaneous Exhibit -- ex4_115                     PDF    247K 
22: EX-99       Miscellaneous Exhibit -- ex4_116                     PDF    126K 
24: EX-99       Miscellaneous Exhibit -- ex4_117                     PDF    200K 
26: EX-99       Miscellaneous Exhibit -- ex4_118                     PDF    298K 
28: EX-99       Miscellaneous Exhibit -- ex4_119                     PDF    153K 
30: EX-99       Miscellaneous Exhibit -- ex4_120                     PDF    204K 
32: EX-99       Miscellaneous Exhibit -- ex4_121                     PDF    413K 
34: EX-99       Miscellaneous Exhibit -- ex4_122                     PDF    100K 
36: EX-99       Miscellaneous Exhibit -- ex4_123                     PDF    177K 
38: EX-99       Miscellaneous Exhibit -- ex8_1                       PDF     54K 


EX-99   —   Miscellaneous Exhibit


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Page 1  
background image
Exhibit 4.122
Page 1
28 September 2007
STRICTLY PRIVATE AND CONFIDENTIAL
Mr John Sayers
DRD (Offshore) Limited
ci- DRDGold Limited
299 Pendoring Avenue,
Blackheath,
Randburg, South Africa
Dear John
Placement of DRD (Offshore) Limited's 78.72% shareholding in Emperor Mines
Limited Joint Mandate Letter
ABN AMRO Morgans Limited (AAM) and Tricom Equities Limited (Tricom),
(together the Brokers) are pleased to submit this joint mandate letter to act as financial
adviser and placement agent to DRD (Offshore) Limited (DRD or the Company) in
relation to the proposed divestment by DRD of all of the 823,391,603 shares it holds in
Emperor Mines Limited (EMP) (the EMP Shares).
1
The sale process
1.1      The sale of the EMP Shares (Sale) will occur by way of bookbuild to be jointly
managed by the Brokers so as to determine demand for the EMP Shares at various sale
prices (Bookbuild).
1.2      The minimum sale price for the Sale of the EMP Shares is 6.8 cents per EMP Share
(Floor Price).
1.3      The Brokers commitment to sell all of the EMP Shares is on a best endeavours basis and
nothing in this mandate letter should be construed as an underwriting commitment or a
commitment to underwrite the Floor Price.
1.4      Following the close of the Bookbuild, DRD will, in consultation with the Brokers,
determine the sale price per EMP Share (Sale Price), which must not be less than the
Floor Price.
1.5      Once the Sale Price has been established, the Brokers are then required to determine the
persons who will purchase all of the EMP Shares in consultation with DRD (the
Allottees), provided always that the sale of the EMP Shares must not result in any
person acquiring voting power to more than 20% of EMP as a result of the purchase of
any of the EMP Shares under the Sale.
1.6      Settlement of the Sale will occur on a maximum of 5 trading days' (as that term is
defined by the ASX Listing Rules) after confirming allocations to Allottees (Settlement
Date).
1.7      DRD may suspend any and all activities under this mandate letter if its execution and
performance would breach Division 3 of Part 7.10 of the Corporations Act 2001 (Cth)
(Corporations Act) or any other applicable insider trading laws.
1.8      Unless the Brokers have otherwise terminated their obligations in accordance with
clause 6 of this letter, each Broker will by 4.00pm on the Settlement Date, pay, or
procure payment, in cleared funds of the gross proceeds of the Sale (the Sale
Proceeds) being the Sale Price multiplied by the number of EMP Shares allocated by
that Broker pursuant to clause 1.6, subject to the receipt of funds from those Allottees and
less authorised fees and expenses determined in accordance with clause 3.
background image
Page 2
1.9     Each Broker is severally liable (as opposed to jointly and severally liable) in respect
of the Brokers obligations under this mandate letter.
1.10    The Brokers will use their best endeavours to complete the Sale of all of the EMP
Shares the subject of the Bookbuild in accordance with the timetable set out in the
schedule to this letter.
1.11    The Brokers each acknowledge and agree that DRD retains the absolute right to sell
any of the EMP Shares it holds outside of the Bookbuild, provided always that DRD
notifies the Brokers of the number of EMP Shares to be sold outside of the Bookbuild
no later than 2 business days prior to the commencement of the roadshows to market
the sale of the EMP Shares. For the purpose of this clause 1.12, a business day is a
day on which banks are open for business in both Queensland, Australia and
Johannesburg, South Africa.
1.12      Nothing in this mandate letter obliges DRD to proceed with:
(a)
the roadshow in relation to the Sale of the EMP Shares if, in DRD's opinion, the
Sale is unlikely to result in DRD being able to sell all of its EMP Shares for a price
not less than the Floor Price;
(b)
the Sale of EMP Shares the subject of the Bookbuild:
(i)
at a price which is below the Floor Price; or
(ii)
if such a Sale will not result in all of the EMP Shares being sold,
and should the Company decide not to proceed with the Sale in those circumstances,
no brokerage fee is payable to the Brokers under clause 3.1.
        Brokers obligations
2.1      Each Broker acknowledges and agrees that:
(a)      no contract of sale in respect of any of the EMP Shares the subject of the
Bookbuild is to be entered into unless and until a prospectus or other disclosure
document prepared in connection with the offering for sale of the EMP Shares has
first been provided to the potential Allottee of those EMP Shares;
(b)      EMP shareholders are not being asked to approve of the Sale for the purposes of
section 611 item 7 of the Corporations Act, such that no one person can acquire
voting power to more than 20% of EMP as a result of the Sale of the EMP
Shares under this mandate letter;
(c)      DRD does not warrant the accuracy or completeness of, and takes no
responsibility for, any information made available to the Brokers by EMP; and
they have no power or authority to provide undertakings of covenants, or make
representations, on behalf of DRD, in connection with the Sale or otherwise;
(d)      DRD has the right, but not the obligation, to have a representative attend any
investor roadshows held, or presentations given, which relate in any way to the
proposed Sale; and
background image
Page 3
(e)      they must not disclose, and must use their best endeavours to ensure that any
person that participates in any way in any investor presentation or roadshow given
in respect of the Sale does not disclose, any information about the proposed Sale
without the prior written consent of DRD, which once given in respect of a
particular statement will be considered to be an authorised statement. Each Broker
must inform DRD immediately upon any person making an unauthorised
statement about the proposed Sale process.
2.2      Each Broker agrees not to do anything in relation to the Sale which would result in a
breach of the Corporations Act by DRD or any other person.
2.3      Each Broker covenants with, and represents and warrants to the Company as at the date
of this letter and at all times up to and including the Settlement Date, and acknowledges
that the Company is relying on such representations and warranties as follows:
(a)
It has observed and will observe all Australian securities laws applicable to the Sale
in all material respects including, without limitation, the Foreign Acquisitions
and Takeovers Act 1975 (Cth) and the takeovers, fundraisings, market
misconduct and financial services licensing provisions of the Corporations Act);
(b)
It has not and will not directly or indirectly, offer, sell or deliver any EMP Shares to
any person in any jurisdiction where it would be unlawful to do so;
(c)
Where it offers the EMP Shares for sale in Australia, it shall only make such offers to
persons who have expressed an interest in purchasing the EMP Shares where such an
offer would not require disclosure pursuant to section 708l8), l10) or l11) of the
Corporations Act;
(d)
Where it offers the EMP Shares for sale in foreign jurisdictions, it shall only make
such offers where such offers can lawfully be made in accordance with the securities
laws of the relevant jurisdiction without the need to prepare a disclosure document
that complies with and/or is registered in, or do any other act, matter or thing in
relation to the Sale in, the jurisdiction in which the offer is made. Each of the Brokers
and the Company acknowledge that it is the intention that the due diligence
committee formed in relation to the preparation of the prospectus will co-ordinate the
request for legal advice in respect of the foreign jurisdictions in which offers for sale
of the EMP Shares may be made, and that that advice is to be made available to the
Brokers to review prior to conducting any roadshow or other presentations in those
jurisdictions. To the extent that the Brokers continue to have concerns in respect of a
particular foreign jurisdiction, then the Company will use its reasonable endeavours
to procure the due diligence committee to make further enquiries to allay those
concerns;
(e)
any person purchasing EMP Shares under the Sale has warranted in favour of DRD
that the purchase of such shares will not result in the purchaser acquiring voting
power to more than 20% of EMP or otherwise breaching the takeovers provisions of
the Corporations Act;
(f)
the approvals, licences and authorities that are necessary to permit the relevant Broker
to enter into an perform its obligations under this mandate letter have been obtained
an remain valid;
(g)
(g) it will not make any public announcements relating in any way to the Sale
without the prior written consent of the Company;
(h)
(h) it will provide DRD with all information required, on a timely basis, to enable
DRD to satisfy its obligations to provide notices of changes in its shareholding in
EMP in accordance with Part 6C.1 of the Corporations Act.
background image
Page 4
3
Fees and expenses
3.1      On the Settlement Date, the Company agrees to pay the Brokers an aggregate fixed
brokerage fee of 1.5% of the proceeds of the Sale of all of the EMP Shares sold
through the Bookbuild, plus a performance fee of A$50,000 for every 0.1 cents per
EMP Share achieved in the Sale Price over the Floor Price, plus GST (if any) on this
fee, which is to be shared equally by the Brokers.
3.2      The Company will reimburse the Brokers for any out of pocket expenses incurred
during the course of the Engagement. Individual expense items over A$2,000 will only
be reimbursed if approved in writing in advance by DRD.
3.3      All fees and other sums payable to the Brokers are payable in Australian dollars. The
Company must pay each Broker all goods and services taxes, or other applicable or
similar taxes, that that Broker is liable (either directly or indirectly) to pay for any
supply under or in connection with the Engagement. If the Company is obliged to make
any deduction or withholding on account of any tax of any nature, the amount payable
is to be grossed up to the extent necessary to ensure that, after such deduction or
withholding, the amount otherwise payable remains unchanged.
3.4      The Company will be responsible for its own legal fees and the costs of any other
advisers engaged by the Company to assist in respect of the Sale.
4
DRD's representations and warranties
4.1      DRD represents and warrants to each Broker as at the date of this mandate letter and
on each day up to and including the Settlement Date that other than as disclosed to the
Brokers prior to signing this mandate letter:
(a)
DRD is a body corporate validly existing under the laws of its place of
incorporation and has power to enter into and comply with its obligations under
this mandate letter;
(b)
all approvals and consents required (if any) to permit DRD to enter into this
mandate letter and to enable performance of this mandate letter by DRD have
been obtained and are valid and subsisting;
(c)
this mandate letter is a valid and binding obligation on DRD and the Sale and
DRD's compliance with this mandate letter will not conflict or breach:
(i)
any agreement or instrument to which DRD is a party or by which it or
any of its properties or assets are bound; or
(ii)
any statute including but not limited to the Corporations Act, rule
including but not limited to the ASTC Settlement Rules, the ASX
Market Rules, the ASX Listing Rules and its constitution) or regulation
applicable to, or any order of any court or governmental agency with
jurisdiction over, DRD, its assets or its properties,
where such a conflict or breach is likely to have a material effect on the capacity
of DRD to sell the EMP Shares;
(d)
DRD is the registered holder and sole legal and beneficial owner of the EMP
Shares and owns the EMP Shares free from all liens, charges, security
interests, claims, equities, pre-emptive rights and other encumbrances other
than those provided for in the Company's constitution;
background image
Page 5
(e)
all information provided to the Brokers in relation to the Sale by or on behalf
of DRD is true, complete and accurate in all material respects, and not materially
misleading or deceptive. DRD will notify the Brokers if it subsequently discovers
that any information provided by it is incomplete, untrue or inaccurate in any
material respect or materially misleading or deceptive.
4.2      DRD acknowledges that the Brokers will rely on these representations and warranties in
performing its obligations under this mandate letter.
4.3      DRD will provide the Brokers and their respective advisers with such access to the
directors and management of, and the auditors and advisers to, the Company and its
related bodies corporate for the purpose of this mandate letter as they may reasonably
require.
5
Confidentiality and announcements
5.1      DRD and the Brokers will consult with each other in respect of any material public
announcements, statements or releases in respect of the Sale.
5.2      Subject to clause 5.3, each Broker on behalf of itself and each of its employees,
partners, consultants, advisers and all parties falling under its authority or having any
relationship with it) shall at all times keep any information provided by or on behalf of
DRD under this mandate letter (Confidential Information) strictly confidential, and shall
not use or permit the use of such information for any purpose other than as stipulated in
this mandate letter and shall not disclose such Confidential Information to any third
party. This confidentiality clause shall continue to apply notwithstanding termination of
this mandate letter.
5.3       Each Broker may disclose Confidential Information:
(a)
where the disclosure of the information is required by law, regulation or order of a
court or regulatory body, or pursuant to governmental action, regulatory
requirement or request (Disclosure), in which case:
(i)
the party making the Disclosure will use reasonable endeavours to consult
with DRD prior to making the Disclosure; and
(ii)
the Disclosure will only disclose that amount of information necessary to
comply with the relevant Disclosure requirement;
(b)
where the information was in the public domain when given, or later comes into
the public domain other than as a result of breach of this mandate letter;
(c)
where the prior written consent of DRD is obtained;
(d)
to any of its officers, employees and advisers who have a need to know of the
information for the purposes of the Sale and who are subject to an obligation to
keep the information strictly confidential.
        Termination
6.1      The Brokers may terminate this mandate letter, without cost or liability to it by notice
to DRD before 4.00pm on the Settlement Date, if any of the following occur:
(a)
default: DRD breaches any clause in this mandate letter in a material respect; or
(b)
withdrawal: the Sale is withdrawn by DRD prior to DRD determining the Sale
Price.
6.2     DRD may terminate this mandate letter at any time prior to determining the Sale Price.
background image
Page 6
6.3     If DRD elects to terminate this mandate after the completion of the institutional
          roadshow to market the potential Sale as a result of the Bookbuild process being
          unsuccessful in, or DRD forming the view that the Bookbuild process is unlikely to be
          successful in, resulting in the sale of all of the EMP Shares for a Sale Price of not less
          than the Floor Price, DRD will incur a termination fee of A$1 00,000 plus GST (if
          any). For the avoidance of doubt,
(a) 
    DRD may terminate this mandate prior to conducting the institutional
roadshow without penalty; and
(b)   DRD may terminate this mandate after completion of the institutional roadshow
without penalty where any merger proposal announced by EMP prior to the
institutional roadshow being conducted is terminated for reasons other than the Sale
of all of DRD's EMP Shares not proceeding. In those circumstances, DRDGold
agrees to reimburse the Brokers for their direct costs associated with the institutional
roadshow within 14 days of being provided with receipts for those costs provided
always that such costs do not exceed A$1 00,000 plus GST), with employees of the
Brokers being charged out for their time in accordance with market rates.
        Indemnity
7.1      Subject to clause 7.2, DRD unconditionally and irrevocably undertakes to indemnify
and keep indemnified each Broker and each of their related bodies corporate and their
respective officers, employees and advisers together the Indemnified Parties) from and
against all claims, demands, damages, losses, costs, expenses and liabilities losses)
finally judicially determined to have been suffered or incurred directly or indirectly as a
result of or in connection with:
(a)
the Sale or the participation in the Sale by the Indemnified Party;
(b)
any material breach of this mandate letter by DRD;
lc) any documentary, stamp or similar transfer or issue tax, including any
interest and penalties, on the Sale, which are or may be required to be paid
by DRD under any relevant jurisdiction.
7.2      The indemnity in clause 7.1 will not be an indemnity against any Losses where and to
the extent that those Losses are finally judicially determined to have resulted from any
fraud, recklessness, willful misconduct or negligence of that Indemnified Party.
7.3      DRD agrees that no claim may be made by it against an Indemnified Party and
DRD unconditionally and irrevocably releases and discharges each Indemnified Party
from any claim that may be made by it to recover from that Indemnified Party any Losses
suffered or incurred by DRD arising directly or indirectly as a result of the participation
of that Indemnified Party in the Sale, except to the extent that those Losses are judicially
determined to have resulted from any fraud, recklessness, willful misconduct or
negligence of that Indemnified Party.
7.4      The indemnity in clause 7.1 is a continuing obligation, separate and independent from
the other obligations of the parties, and survives termination or completion of this
mandate letter.
7.5      For the purpose of this mandate letter, each Broker is deemed to be acting as agent and
trustee on behalf of and for the benefit of all of their respective Indemnified Parties.
background image
Page 7
8
Conflicts of interest
8.1     The Brokers and each of their respective related bodies corporate may be involved in
a wide range of investment banking and other activities including investment
management, corporate finance and securities issuing, trading and research) out of
which conflicting interests or duties may arise. DRD agrees the Brokers duties and
obligations to DRD are solely as provided for in this agreement. Other than expressly
set out in this agreement, the Brokers do not owe any fiduciary duties to DRD in
relation to acting for and advising DRD under this agreement. DRD agrees that the
investment, management and trading activities of the Brokers' and their respective
related bodies corporate will not be restricted by this joint mandate letter provided that
the Brokers' do not use any non-public or Confidential Information received from
DRD and, on the performance of this joint mandate letter, its circulation or the provision
of it by the Brokers is restricted to their respective directors, officers, employees,
contractors, agents or advisers who need to know of it in connection with the Brokers
acting for DRD. Each Broker must ensure that an effective Chinese wall' is established
to protect the confidentiality of any information provided by or on behalf of DRD to the
Broker in respect of this mandate letter.
8.2     Neither Broker nor their respective related bodies corporate will have any duty to
disclose to DRD or utilise for DRD's benefit any non-public information acquired in the
course of providing services to any other person, engaging in any transaction on its own
account or otherwise) or otherwise carrying on its business.
8.3      DRD accepts that permanent or ad-hoc arrangements within divisions of either of the
Brokers or their respective related bodies corporate may be used to achieve 8.2 above
and that locating directors, officers or employees in separate workplaces is not
necessary for that purpose.
8.4     The Brokers inform DRD that they reserve the right, but has no obligation, to purchase
up to 10% of the EMP Shares to be sold through the Bookbuild, either as principal or on
behalf of its employees, provided always that:
(a)
the price of such Sales is not less than the Floor Price; and
(b)
any applications to acquire EMP Shares at a higher price under the Bookbuild are
satisfied in full before any EMP Shares are sold to either of the Brokers either as
principal or on behalf of its employees).
9
Waiver and variation
Any clause under this mandate letter may only be waived in writing by the party
granting the waiver or varied in writing and signed by the parties.
10       Governing law
This mandate letter and the transactions contemplated by this mandate letter are
governed by, and construed in accordance with, the laws in force in Queensland and
the parties irrevocably submit to the non-exclusive jurisdiction of the courts of
Queensland.
11       Counterparts
This mandate letter may be executed in counterparts and the counterparts taken
together will be regarded as one instrument.
Would you please confirm your acceptance of the above terms by signing below and
returning to us.
background image
Page 8
Yours sincerely
Managing Director
Head of Corporate
DRD acknowledges and accepts the above terms.
DRD (Offshore) Limited
Signature of authorised person
Date:

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/12/08  SEC                               UPLOAD9/20/17    1:33K  Drdgold Ltd.
 8/06/08  SEC                               UPLOAD9/20/17    1:46K  Drdgold Ltd.
 6/10/08  SEC                               UPLOAD9/20/17    1:51K  Drdgold Ltd.
 6/09/08  SEC                               UPLOAD9/20/17    1:46K  Drdgold Ltd.
Top
Filing Submission 0001205613-07-000166   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 3:41:00.1pm ET